ramelteon has been researched along with Cancer of Endometrium in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwashita, M; Izawa, T; Kobayashi, Y; Osanai, K; Otsu, M; Sakai, K | 1 |
1 other study(ies) available for ramelteon and Cancer of Endometrium
| Article | Year |
|---|---|
Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Depression, Chemical; Endometrial Neoplasms; Female; Gene Expression; Humans; Indenes; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2017 |